Association between preeclampsia and the CXC chemokine family (Review)

Experimental and Therapeutic Medicine

Volumn 9, Issue 5, 2015, Pages 1572-1576

  Liu, Xijing ^a   Dai, Li ^a   Zhou, Rong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Angiogenesis; CXC chemokines; Preeclampsia; Trophoblast invasion

Indexed keywords

ALPHA CHEMOKINE; CD82 ANTIGEN; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL14 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FIBROBLAST GROWTH FACTOR 2; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 8; PLACENTAL GROWTH FACTOR; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; CELL FUNCTION; CELL MIGRATION; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MATERNAL HYPERTENSION; PATHOGENESIS; PREECLAMPSIA; PROTEIN EXPRESSION; PROTEINURIA; REGULATORY MECHANISM; SURVIVAL RATE; TROPHOBLAST;

EID: 84925034581     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2337     Document Type: Article

References (60)

1. Roberts JM and Hubel CA: The two stage model of preeclampsia: variations on the theme. Placenta 30 (Suppl A): S32-S37, 2009.
2. Raymond D and Peterson E: A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv 66: 497-506, 2011.
3. Redman CW: Platelets and the beginnings of preeclampsia. N Engl J Med 323: 478-480, 1990.
4. Carty DM, Delles C and Dominiczak AF: Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med 18: 186-194, 2008.
5. Gauster M, Moser G, Orendi K and Huppertz B: Factors involved in regulating trophoblast fusion: potential role in the development of preeclampsia. Placenta 30 (Suppl A): S49-S54, 2009.
6. Goldman-Wohl D and Yagel S: Regulation of trophoblast invasion: from normal implantation to pre-eclampsia. Mol Cell Endocrinol 187: 233-238, 2002.
7. Kim YN, Lee DS, Jeong DH, et al: The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn 29: 464-470, 2009.
8. Steinberg G, Khankin EV and Karumanchi SA: Angiogenic factors and preeclampsia. Thromb Res 123 (Suppl 2): S93-S99, 2009.
9. Cerdeira AS and Karumanchi SA: Angiogenic factors in preeclampsia and related disorders. Cold Spring Harb Perspect Med 2: pii: a006585, 2012.
10. Hirashima C, Ohkuchi A, Matsubara S, et al: Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset. Hypertens Res 31: 1541-1548, 2008.
11. Zlotnik A and Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127, 2000.
12. Keeley EC, Mehrad B and Strieter RM: Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 28: 1928-1936, 2008.
13. Addison CL, Daniel TO, Burdick MD, et al: The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 165: 5269-5277, 2000.
14. Strieter RM, Polverini PJ, Kunkel SL, et al: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270: 27348-27357, 1995.
15. Mehrad B, Keane MP and Strieter RM: Chemokines as mediators of angiogenesis. Thromb Haemost 97: 755-762, 2007.
16. Maione TE, Gray GS, Petro J, et al: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247: 77-79, 1990.
17. Keeley EC, Mehrad B and Strieter RM: Chemokines as mediators of tumor angiogenesis and neovascularization. Exp Cell Res 317: 685-690, 2011.
18. Loukinova E, Dong G, Enamorado-Ayalya I, et al: Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 19: 3477-3486, 2000.
19. Murphy PM: The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 12: 593-633, 1994.
20. Ahuja SK and Murphy PM: The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem 271: 20545-20550, 1996.
21. Loetscher M, Gerber B, Loetscher P, et al: Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184: 963-969, 1996.
22. Kakinuma T and Hwang ST: Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 79: 639-651, 2006.
23. Tanegashima K, Suzuki K, Nakayama Y, et al: CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis. FEBS Lett 587: 1731-1735, 2013.
24. Balabanian K, Lagane B, Infantino S, et al: The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 280: 35760-35766, 2005.
25. Strieter RM, Burdick MD, Mestas J, et al: Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42: 768-778, 2006.
26. Yoneda J, Kuniyasu H, Crispens MA, et al: Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90: 447-454, 1998.
27. Arenberg DA, Keane MP, DiGiovine B, et al: Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 102: 465-472, 1998.
28. Addison CL, Belperio JA, Burdick MD and Strieter RM: Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer 4: 28, 2004.
29. White ES, Flaherty KR, Carskadon S, et al: Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 9: 853-860, 2003.
30. Arenberg DA, Kunkel SL, Polverini PJ, et al: Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97: 2792-2802, 1996.
31. Moore BB, Arenberg DA, Stoy K, et al: Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 154: 1503-1512, 1999.
32. Wente MN, Keane MP, Burdick MD, et al: Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett 241: 221-227, 2006.
33. Moser B and Loetscher P: Lymphocyte traffic control by chemokines. Nat Immunol 2: 123-128, 2001.
34. Lasagni L, Francalanci M, Annunziato F, et al: An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197: 1537-1549, 2003.
35. Ehlert JE, Addison CA, Burdick MD, et al: Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol 173: 6234-6240, 2004.
36. Yang J and Richmond A: The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther 9: 846-855, 2004.
37. Strieter RM, Burdick MD, Gomperts BN, et al: CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 16: 593-609, 2005.
38. Cole KE, Strick CA, Paradis TJ, et al: Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187: 2009-2021, 1998.
39. Coughlin CM, Salhany KE, Wysocka M, et al: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101: 1441-1452, 1998.
40. Borgström P, Discipio R and Maione TE: Recombinant platelet factor 4, an angiogenic marker for human breast carcinoma. Anticancer Res 18: 4035-4041, 1998.
41. Gupta SK and Singh JP: Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol 127: 1121-1127, 1994.
42. Sgadari C, Angiolillo AL, Cherney BW, et al: Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 93: 13791-13796, 1996.
43. Arenberg DA, Kunkel SL, Polverini PJ, et al: Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184: 981-992, 1996.
44. Arenberg DA, White ES, Burdick MD, et al: Improved survival in tumor-bearing SCID mice treated with interferon-gamma-inducible protein 10 (IP-10/CXCL10). Cancer Immunol Immunother 50: 533-538, 2001.
45. Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 4: 540-550, 2004.
46. Müller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56, 2001.
47. Zagzag D, Lukyanov Y, Lan L, et al: Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86: 1221-1232, 2006.
48. Sun X, Cheng G, Hao M, et al: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 29: 709-722, 2010.
49. Burns JM, Summers BC, Wang Y, et al: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203: 2201-2213, 2006.
50. Maishi N, Ohga N, Hida Y, et al: CXCR7: a novel tumor endothelial marker in renal cell carcinoma. Pathol Int 62: 309-317, 2012.
51. Song EY, Shurin MR, Tourkova IL, et al: Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells. Cancer Res 70: 4394-4401, 2010.
52. Tessema M, Klinge DM, Yingling CM, et al: Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene 29: 5159-5170, 2010.
53. Jovanovic M, Stefanoska I, Radojcic L and Vicovac L: Interleukin-8 (CXCL8) stimulates trophoblast cell migration and invasion by increasing levels of matrix metalloproteinase (MMP)2 and MMP9 and integrins alpha5 and beta1. Reproduction 139: 789-798, 2010.
54. Kuang H, Chen Q, Zhang Y, et al: The cytokine gene CXCL14 restricts human trophoblast cell invasion by suppressing gelatinase activity. Endocrinology 150: 5596-5605, 2009.
55. Kuang H, Chen Q, Fan X, et al: CXCL14 inhibits trophoblast outgrowth via a paracrine/autocrine manner during early pregnancy in mice. J Cell Physiol 221: 448-457, 2009.
56. Li MQ, Tang CL, Du MR, et al: CXCL12 controls over-invasion of trophoblasts via upregulating CD82 expression in DSCs at maternal-fetal interface of human early pregnancy in a paracrine manner. Int J Clin Exp Pathol 4: 276-286, 2011.
57. Gotsch F, Romero R, Friel L, et al: CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia? J Matern Fetal Neonatal Med 20: 777-792, 2007.
58. Boij R, Svensson J, Nilsson-Ekdahl K, et al: Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia. Am J Reprod Immunol 68: 258-270, 2012.
59. Schanz A, Winn VD, Fisher SJ, et al: Pre-eclampsia is associated with elevated CXCL12 levels in placental syncytiotrophoblasts and maternal blood. Eur J Obstet Gynecol Reprod Biol 157: 32-37, 2011.
60. Gui S, Ni S, Jia J, Gong Y, Gao L, Zhang L and Zhou R: Inconformity of CXCL3 plasma level and placenta expression in preeclampsia and its effect on trophoblast viability and invasion. PLoS One 9: e114408, 2014.